BioSpace News Archive

Kansas Health Information Network, Inc., DBA KONZA announced today it is one of the first organizations to have its application approved to continue to the testing and onboarding phase to become a Qualified Health Information Network (QHIN) under the Trusted Exchange Framework and Common Agreement (TEFCA) by the Office of the National Coordinator (ONC) for Health IT.

The Canadian Medical Protective Association (CMPA) is pleased to share key findings learned from its peer-reviewed study, Diagnostic delays in sepsis: Lessons learned from a retrospective study of Canadian medico-legal claims.

Pixium Vision SA announces that it has terminated its Convertible Note financing agreement with the European Select Growth Opportunities Fund, a US-based investor specializing in healthcare.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.

Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel tumor necrosis factor superfamily receptor antagonist antibodies, announced updates on the company’s DOMab™ platform.

MDxHealth SA announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score test under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”) today announced the acquisition from RadioMedix, Inc. (“RadioMedix”) of the investigational new drug application (“IND”) for an ongoing Phase 2 clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen (“PSMA”) expressed on prostate cancers.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the fourth quarter and full year 2022 before market open on Monday, March 6, 2023.

Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”) is providing webcast access to their virtual R&D Day, being held on Tuesday, February 14, 2023.